Friday, April 23, 2021

High Efficacy of a Low Dose Candidate Malaria Vaccine

Good news!

However, why are we capable of developing a dozen or more effective vaccines in several countries by multiple companies against SARS-CoV-2 within months, but we are still struggling to defeat plasmodium falciparum?

High Efficacy of a Low Dose Candidate Malaria Vaccine, R21 in 1 Adjuvant Matrix-M™, with Seasonal Administration to Children in Burkina Faso (open access)

No comments: